BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, said on Monday that it has priced its initial public offering of 12.5 million American Depositary Shares (ADSs) in a range of $15 to $17 per ADS. Each ADS represents one common share of the company.
The company also expects to grant underwriters a 30-day option to purchase up to an additional 1.875 million ADSs to cover any over-allotments.
J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen are serving as joint book-running managers for the offering.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
